Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar:266:113877.
doi: 10.1016/j.jpeds.2023.113877. Epub 2023 Dec 20.

Secular Trends in Patent Ductus Arteriosus Management in Infants Born Preterm in the National Institute of Child Health and Human Development Neonatal Research Network

Dinushan C Kaluarachchi  1 , Matthew A Rysavy  2 , Benjamin A Carper  3 , Valerie Y Chock  4 , Matthew M Laughon  5 , Carl H Backes  6 , Tarah T Colaizy  7 , Edward F Bell  7 , Patrick J McNamara  7
Affiliations

Secular Trends in Patent Ductus Arteriosus Management in Infants Born Preterm in the National Institute of Child Health and Human Development Neonatal Research Network

Dinushan C Kaluarachchi et al. J Pediatr. 2024 Mar.

Abstract

We evaluated changes in patent ductus arteriosus (PDA) diagnosis and treatment from 2012 through 2021 in a network of US academic hospitals. PDA treatment decreased among infants born at 26-28 weeks but not among infants born at 22-25 weeks. Rates of indomethacin use and PDA ligation decreased while acetaminophen use and transcatheter PDA closure increased.

Keywords: patent ductus arteriosus; preterm infant; secular trends.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest D.C.K. serves as a consultant for ONY Biotech Inc. C.H.B. has following disclosures; Abbott Laboratories: funding of ongoing multicenter trial, in partnership with National Institutes of Health, entitled PIVOTAL (NCT05547165). Abbott Laboratories has no part in the design or execution of PIVOTAL. P.J.M. serves as a consultant for Abbot Laboratories and Aspect Ltd. The other authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
PDA diagnosis and treatment from 2012-2021 for the entire study cohort
Figure 2.
Figure 2.
PDA diagnosis and treatment from 2012-2021 for gestational age subgroups
See this image and copyright information in PMC

References

    1. Bell EF, Hintz SR, Hansen NI, Bann CM, Wyckoff MH, DeMauro SB, et al. Mortality, in-hospital morbidity, care practices, and 2-year outcomes for extremely preterm infants in the US, 2013-2018. JAMA. 2022;327:248–63. - PMC - PubMed
    1. Hamrick SEG, Sallmon H, Rose AT, Porras D, Shelton EL, Reese J, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2020;146: e20201209. - PMC - PubMed
    1. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol. 2010;30: 241–52. - PubMed
    1. Altit G, Saeed S, Beltempo M, Claveau M, Lapointe A, Basso O. Outcomes of extremely premature infants comparing patent ductus arteriosus management approaches. J Pediatr. 2021;235:49–57.e2. - PubMed
    1. Relangi D, Somashekar S, Jain D, Vanbuskirk S, Bancalari E, Sosenko I, et al. Changes in patent ductus arteriosus treatment strategy and respiratory outcomes in premature infants. J Pediatr. 2021;235:58–62. - PubMed